Key result
The prothrombin G20210A mutation significantly increased the risk of pregnancy complications compared to wild-type controls (57.9% vs 25.1%, RR 2.3).
Why the study?
To study the association between high prothrombin (Factor II) activity in blood plasma in G20210A mutation carriers and the development of great obstetrical syndromes.
Does the prothrombin G20210A mutation and associated high Factor II activity increase the risk of pregnancy complications such as preeclampsia and fetal growth retardation?
Population
290 pregnant women (average age 31.7±4.7 years old)
Comparison
140 G20210A patients vs 150 wild G20210G type controls
Design
Prospective clinical cohort study
Authors
Loading...
May support preconception Factor II testing for risk stratification in mutation carriers; hypothesis-generating and requires prospective validation before practice change.
Cohort (n=290)
No
Does the prothrombin G20210A mutation and associated high Factor II activity increase the risk of pregnancy complications such as preeclampsia and fetal growth retardation?
Relative Risk: 2.3 (95% CI 1.7–3.1)
Absolute Event Rate: 57.9% vs 25.1%
p-value: p=<0.0001
High Factor II activity in pregnant women with the prothrombin G20210A mutation is strongly associated with and predictive of severe obstetrical complications like preeclampsia.
Nikolaeva et al. (2020) conducted a cohort in Pregnancy complications (n=290). Prothrombin G20210A mutation vs. Wild G20210G genotype was evaluated on Pregnancy complications (RR 2.3, 95% CI 1.7-3.1, p=<0.0001). The prothrombin G20210A mutation significantly increased the risk of pregnancy complications compared to wild-type controls (57.9% vs 25.1%, RR 2.3).
Synapse has enriched 4 closely related papers on similar clinical questions. Consider them for comparative context: